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Abstract: Clinical trials are one of the key study designs in the evolving field of comparative 
effectiveness research. Evaluating the effectiveness of interventions in real-world settings is com-
plex and demands a rethinking of the traditional clinical trial approach as well as transformation 
of the clinical trial landscape. Novel strategies and refinement of existing approaches have been 
proposed to generate evidence that can guide health care stakeholders in their decision process. 
The purpose of this review is to discuss clinical trial design approaches in the era of compara-
tive effectiveness research. We will focus on aspects relevant to the type of clinical trial, study 
population and recruitment, randomization process, outcome measures, and data collection.
Keywords: review, clinical trial, comparative effectiveness research
Introduction
Comparative effectiveness research (CER) aims to provide health care stakeholders, 
including patients, clinicians, and policymakers, with evidence necessary to make 
informed health care decisions.1 One important aspect of CER is the generation of 
evidence that is applicable to a broad patient population and reflects real-world circum-
stances, allowing efficient translation and implementation of findings into patient care. 
Clinical trials are one of the key study designs in CER and can be utilized to evaluate 
the effectiveness of a broad spectrum of health care interventions such as treatments, 
behavioral interventions, clinical evaluation strategies, health care delivery methods, 
and policy interventions.2 However, conducting a clinical trial in a real-world setting 
is complex and demands a shift in the traditional clinical trial paradigm.3
The investment of over $1 billion in CER through the American Recovery and 
Reinvestment Act of 2009 has resulted in a growing demand and interest in CER 
in the research community in the USA. Funding agencies including the Agency for 
Healthcare Research and Quality and the Patient-Centered Outcomes Research Institute 
have issued proposal requests to develop CER infrastructure and conduct CER studies 
including pragmatic clinical trials.4 The governmental commitment and investment in 
CER provides the research community with exciting opportunities to address important 
CER questions. However, many health researchers and decision makers may not yet 
be familiar with clinical trial design features and concepts in the rapidly evolving CER 
field. The purpose of this review is to provide a broad overview of clinical trial design 
concepts in the context of CER and to discuss some aspects relevant to the design 
and interpretation of clinical trials. Within the scope of this review, we will focus on 
the definition of trial type, study population and recruitment, randomization process, 





 outcomes measures, and data collection. We will discuss 
some methodological points to consider when designing a 
clinical trial, acknowledging that we are unable to cover every 
aspect that has been proposed in this evolving field.
Type of trial
Effectiveness or pragmatic trials have been proposed as 
one key trial design in CER to generate evidence that can 
be efficiently translated into patient care. An effectiveness 
or pragmatic trial seeks to answer the question whether 
an intervention works under usual conditions. An efficacy 
or explanatory trial is designed to evaluate whether an 
intervention works under ideal circumstances.5,6 These 
distinctions also have implications for the design and 
interpretation of the trial. A pragmatic/effectiveness trial is 
designed to determine the effectiveness of an intervention 
in a real-world setting and will include a broad spectrum of 
patients. The trial will be embedded in routine care or reflect 
real-world circumstances of patient care. The intervention 
will be compared with an alternative intervention or usual 
care. The trial design will allow a certain degree of flex-
ibility in administering the intervention and in following up 
patients without compromising the internal validity of the 
trial. In contrast, to determine the efficacy of an intervention, 
an efficacy/explanatory trial will enroll a selective patient 
population, likely to be highly responsive to the intervention. 
The intervention will be compared with placebo or a well con-
trolled alternative intervention. The trial will be performed 
in a tightly  controlled study setting with little flexibility and 
patients will be closely monitored and followed.6
Both efficacy and effectiveness trials add valuable 
findings to the whole body of evidence and the choice of 
trial should be guided by the underlying research question. 
Understanding the purpose and design features of the trial are 
important for the interpretation of the trial and the generaliz-
ability of trial results. Results of an efficacy trial indicating a 
beneficial effect do not allow the conclusion that the interven-
tion will always work in usual practice, whereas a “negative” 
efficacy trial strongly suggests that the intervention would 
not work under usual conditions. An intervention that has 
been demonstrated to be effective under usual conditions 
will probably show similar results under ideal circumstances, 
whereas a “negative” effectiveness trial does not prove that 
its intervention cannot work under other circumstances.
However, labels such as pragmatic or explanatory are an 
oversimplification and imply a dichotomy. In reality, a trial is 
rarely completely pragmatic or explanatory and will be on a 
continuum between these two extremes. To provide guidance for 
trial design and to support trialists in the evaluation of the degree 
of pragmatism, a pragmatic-explanatory continuum indicator 
summary (PRECIS) tool has been developed by an interna-
tional group of trialists.6 The PRECIS instrument describes ten 
domains that affect the degree to which a trial is pragmatic or 
explanatory (Table 1). The graphical representation of the ten 
domains is a useful instrument to identify those domains that 
are not as pragmatic or explanatory as the trial designer desires 
(Figure 1). The PRECIS instrument has been primarily devel-
oped to guide the trial design at the planning stage but may also 
have an application in peer reviews from study reports.
In a recently published study, the PRECIS criteria were 
applied to the POWER (Practice-Based Opportunities for Weight 
Reduction) trials.7 The POWER trials were three individual 
studies designed to test the effectiveness of interventions for 
obesity treatment in primary care settings. As part of a com-
mon National Institutes of Health funding mechanism, all 
trials shared certain design  features.  Trial-specific elements 
included different types of interventions and secondary outcome 
measures. Two raters from each trial and three independent 
raters were asked to rate the three studies on the ten PRECIS 
domains, using a 0–4 point scale (0, completely explanatory; 
4, completely  pragmatic). In Figure 1, the PRECIS diagram of 
the “POWER  Hopkins” study7 is presented. Overall, all trials 
were rated in a moderate range on the PRECIS scale, with mean 
scores ranging from 1.82 to 2.36. The inter-rater reliability on 
the composite PRECIS score was high (r=0.88) and there was 
moderate agreement on the individual level. Despite the small 
sample size, the study is an important first step to evaluate 
the applicability of the PRECIS criteria in post hoc reviews. 
Table 1 Ten domains of the PReCiS model
Participants
 Participant eligibility criteria
interventions and expertise
  Experimental intervention – flexibility
 experimental intervention – practitioner expertise
  Comparison intervention – flexibility
 Comparison intervention – practitioner expertise
Follow-up and outcomes
 Follow-up intensity
 Primary trial outcome
Compliance/adherence
 Participant compliance with “prescribed” intervention
 Practitioner adherence to study protocol
Analysis
 Analysis of primary outcome
Note: Reprinted from the Journal of Clinical epidemiololgy, 62(5), Thorpe Ke, 
Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator 
summary (PReCiS): a tool to help trial designers, 464–475, Copyright 2009, with 
permission from elsevier.6
Abbreviation: PReCiS, pragmatic-explanatory continuum indicator summary.
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In addition, the authors introduced a scoring system to more 
objectively quantify the degree of pragmatism. It is unclear to 
date how the degree of pragmatism of a trial will impact the 
adoption and implementation of findings in patient care. Hope-
fully, future studies in the field will help to define how the choices 
made at the design stage can affect the translation into care.
Another important concept to further define and to clas-
sify clinical trials is according to the underlying research 
hypothesis.
In the context of CER, noninferiority trials are impor-
tant since they can be used to guide the decision process 
between two interventions that have similar therapeutic 
effects but differ in terms of other aspects relevant to stake-
holders, such as costs, adverse event profile, and/or route of 
administration.8 The noninferiority trial aims to show that the 
difference between the treatment of interest and the refer-
ence treatment (active control) is less than the  prespecified 
 noninferiority margin.9 Figure 2 displays a schematic pre-
sentation of the possible scenarios of observed treatment 
differences in noninferiority trials.
The design and quality of a noninferiority trial depends on 
the proper choice of the noninferiority margin. Defining the 
noninferiority margin can be complex and quiet challenging. 
Factors that can provide guidance in the development of non-
inferiority are evidence from previous studies, preliminary 
data, and/or clinical judgment. Sufficient evidence from 
previous efficacy studies or preliminary data is very helpful 
in allowing the trialists to make reasonable assumptions about 
an anticipated effect of the reference treatment. However, 
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Figure 1 Pragmatic-explanatory continuum indicator summary (PReCiS) tool examples.
Notes: (A) To create a wheel graph, mark each spoke to represent the location on the explanatory (hub) to pragmatic (“rim”) continuum for each domain and connect 
the dots. Reprinted from the Journal of Clinical epidemiololgy, 62(5), Thorpe Ke, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary 
(PReCiS): a tool to help trial designers, 464–475, Copyright 2009, with permission from elsevier.6 (B) example of a PReCiS tool that indicates a highly pragmatic trial. 
(C) example of a PReCiS tool that indicates a highly explanatory design. (D) The study was rated by nine raters on a scale from 0 to 4. The mean value for each criterion 
was graphed. Copyright ©. Adapted from Health Research and educational Trust. Glasgow Re, Gaglio B, Bennett G, et al. Applying the PReCiS criteria to describe three 
effectiveness trials of weight loss in obese patients with comorbid conditions. Health Serv Res. 2012;47(3 Pt 1):1051–1067, with permission from John wiley & Sons, Ltd.7
Abbreviations: e, explanatory; POweR, Practice-Based Opportunities for weight Reduction.





evidence for the definition of the noninferiority margin. First, 
patient populations enrolled in previous efficacy trials may be 
highly selective and not representative of the targeted popula-
tion in the noninferiority trial. Second, trials demonstrating 
a beneficial effect of the reference treatment must have been 
conducted recently enough to ensure that no substantial 
changes in medical practice and important medical advances 
occurred. Third, the chosen endpoint in the planned trial must 
be sensitive to the proposed effect in both the intervention and 
reference group to demonstrate a true difference.10
Many trials have to enroll a chronic disease population in 
order to address important CER hypotheses that are pertinent 
to real-world patient care. Designing a noninferiority trial 
in a patient population with chronic disease is particularly 
challenging as previous evidence about possible anticipated 
effect sizes may be lacking for this specific patient popula-
tion, cointerventions may occur, and patients may change 
their treatment regime throughout the trial. In addition, 
efficacy studies can fail to distinguish between treatment and 
placebo effect, or the effect can vary according to the type 
of placebo used in some chronic conditions. This makes a 
noninferiority trial difficult to design.11 Some strategies, such 
as stratification, are available at the design stage to control for 
anticipated or known cointerventions. However, stratification 
of multiple factors complicates the trial design and it may be 
impossible to anticipate any possible  cointervention upfront. 
Although the randomization process ideally balances the 
 possible cointerventions between the groups, the possibil-
ity that the effect will be diluted and results will be biased 
toward the null cannot be ruled out. In the context of a nonin-
feriority trial, a bias toward the null has special implications 
as it can lead to the false conclusion of noninferiority.
Study population and recruitment
Recruitment of a large representative study population 
in a timely and cost-efficient manner is one of the major 
challenges in the CER field. To assure generalizability of 
results, an effectiveness trial aims to include a broad and 
representative study population. In particular, the inclusion 
of populations that have been traditionally underrepre-
sented in clinical trials such as the elderly, minorities, and 
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Figure 2 Possible scenarios of observed treatment differences in non-inferiority trials.
Notes: error Bars indicate 2-sided 95% confidence intervals (CIs). Δ indicates the non-inferiority margin. (A), if the Ci lies wholly left of zero, the new treatment is superior. 
(B and C), if the CI lies to the left of Δ and includes zero, the new treatment is noninferior but not shown to be superior. (D and E), if the CI includes Δ and zero, the 
difference is nonsignificant but the result regarding noninferiority is inconclusive. (F), if the CI is wholly above Δ, the new treatment is inferior. Copyright © (2006) American 
Medical Association. All rights reserved. Adapted from Piaggio G, elbourne DR, Altman DG, Pocock SJ, evans SJ; CONSORT Group. Reporting of noninferiority and 
equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295(10):1152–1160.8
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comparative effectiveness trials addressing important gaps 
in the field require a large sample size to demonstrate effec-
tiveness of interventions and may therefore not be feasible to 
conduct. A long recruitment process is not desirable because 
it increases costs and unnecessarily delays the translation 
of evidence into patient care. Utilization of existing health 
care infrastructures, such as registries, health insurances, and 
primary care networks, for trial recruitment is a promising 
approach to overcome some of these challenges.
TASTE (Thrombus Aspiration in ST-Elevation  Myocardial 
Infarction in Scandinavia) is an example of a recently 
published clinical trial that utilized the infrastructure of a 
population-based national registry, SCAAR (the  Swedish 
Coronary Angiography and Angioplasty Registry), to establish 
feasibility and to facilitate patient enrollment and data collec-
tion.12 This government-funded registry included data from all 
29 Swedish and one Icelandic coronary intervention centers. 
The patients were randomized using an online randomization 
tool within the SCAAR database and the intervention was 
embedded in routine care. Using the existing registry infra-
structure, the investigators were able to recruit and randomize 
over 6,000 patients between June 2000 and September 2012 
at an incremental cost of $50 per patient.13
MI FREE (Post-Myocardial Infarction Free Rx Event 
and Economic Evaluation Trial) is an example of a cluster 
randomized trial that was conducted within a large insur-
ance system (Aetna) in the USA. The aim of the trial was to 
compare the effectiveness of full prescription drug coverage 
for statins, beta-blockers, angiotensin-converting enzyme 
inhibitors, and angiotensin II receptor blockers versus usual 
prescription coverage in the secondary prevention of myo-
cardial infarction. Hospital discharge claims were evaluated 
by the insurance provider to identify eligible patients with 
a discharge diagnosis of new acute myocardial infarction. 
 Randomized assignments to the two insurance benefits 
groups occurred at the level of the plan sponsor. During the 
total study period of 34 months, 5,855 patients were included 
in the trial and followed for a minimum of 1 year. Outcome 
information has been ascertained through Aetna’s health care 
utilization databases.14
Although both the registry-based and insurance-based 
designs are promising and novel concepts of efficient 
and cost-effective recruitment of a large number of trial 
participants, there are some limitations to these designs 
worth considering. Despite the broad inclusion criteria of 
the TASTE trial, approximately 40% of registry patients 
did not enter the trial, mainly because they were unable 
to provide informed consent. These patients had a higher 
30-day mortality rate when compared with the enrolled 
patient population, which limits the generalizability of the 
study results.12 Choudry and Shrank shared their experience 
with designing the MI FREE trial in an insurance setting and 
discussed several challenges.15 Noteworthy in the context 
of patient recruitment and study population characteristics, 
the potential inaccuracy of claims-based identification 
methods, the impact of claims lag on the timely enrollment 
of subjects, and the reluctance of patients to participate in 
insurance-based interventions were described as challenges 
the trialists faced throughout the trial. In addition, the trial 
included neither patients over 65 years old as they receive 
health benefits through Medicare nor those patients who 
received health benefits through other mechanisms.
Recruitment of patients through primary care practices and 
community-based health care providers is another important 
strategy for assembling a study population that reflects real-
world patient care. In particular, primary care practices may 
give access to multimorbid and elderly patients, a population 
typically underrepresented in clinical trials.16 Practice-based 
research networks have been developed and initiated world-
wide, and provide an infrastructure for conducting research in 
primary care settings.17 Recruitment of participants in primary 
care settings may be associated with some unique challenges. 
When clinicians and/or practice staff are involved in the 
screening and enrolling process, barriers such as lack of time 
and resources, concerns with the study protocol, and the pos-
sible negative impact on the patient-clinician relationship can 
affect the success of recruitment. In addition, some primary 
care practices lack the infrastructure necessary to recruit and 
conduct research.18 Proposed strategies to overcome some of 
these recruitment difficulties in primary care include identifica-
tion of eligible patients through electronic health records and 
minimizing the impact on general practice operations, but it is 
unclear to date whether these strategies can be applied to and 
adopted by the majority of primary care settings or whether 
individually tailored strategies are necessary.19–21
Utilization of existing health care infrastructures for 
patient recruitment may not assure the participation of ethnic 
minorities and other underrepresented populations in clinical 
trials. Factors impacting minority clinical trial enrollment 
range from individual to policy level factors, so strategies to 
enhance minority recruitment possibly require interventions 
at multiple levels. A framework to develop and implement 
an institutional strategy to increase minority recruitment in 
therapeutic cancer trials at a US academic institution has been 
published recently.22 Within 5 years after implementation of 
structural changes on four different levels, minority accrual 





to therapeutic trials increased from 12% to 14%. Another 
strategy that has been proposed to enhance minority par-
ticipation in clinical research is engagement of community 
members in research activities through community-based 
participatory research.23 Both implementing changes at 
the institutional level and community-based participatory 
research are promising approaches to address the underrepre-
sentation of minority groups in clinical trials. However, these 
approaches require long-term commitment and support from 
institutions and researchers to implement structural changes 
at the institutional level as well as to build and sustain com-
munity partnerships.
Randomization process
Many research questions in the CER field do not allow 
 randomization at the individual level. They may require a 
cluster randomized trial design because interventions are 
delivered at the system level or because individual allocation 
of the intervention creates the possibility of contamination 
between those who receive the intervention and those who do 
not, either through the patients or the provider who delivers 
the intervention. In a cluster randomized trial, the intervention 
is randomly assigned to a group (ie, cluster) of patients and 
each patient within a cluster receives the same intervention. 
James et al provide an example of a cluster randomized trial 
designed to test system interventions to promote colon cancer 
screening among underinsured and uninsured patients.24 In 
this pragmatic clinical trial, community health centers will 
be randomly assigned to evidence-based implementation 
strategies for increasing colorectal cancer screening. The pri-
mary outcome, colon cancer screening rates, will be assessed 
at the patient level. Implementation outcomes, defined 
according to the RE-AIM (Reach, Efficacy/Effectiveness, 
Adoption, Implementation, and Maintenance) conceptual 
framework,25 will be collected at the patient, provider, and 
practice levels.
Compared with an individual randomized trial, the cluster 
trial is more complex to design and execute, and poses some 
methodological challenges.26,27 Allocating interventions to 
a cluster of patients has important implications for both the 
sample size calculations and the analyses approach. Patients 
within a cluster may share certain similarities and cannot be 
considered as independent observations. Independence is 
one important assumption of standard statistical tests used 
for sample size calculations, and the trial designer needs to 
account for possible correlations of patient characteristics 
including the outcome of interest within a cluster. The 
intraclass correlation coefficient, defined as the ratio of the 
variance between clusters divided by the sum of the variance 
between clusters plus the variance among patients within a 
cluster, quantifies the amount of agreement in a characteristic 
(ie, the primary endpoint of a study) between individuals of 
the same cluster.26 Estimation of the intraclass correlation 
coefficient is one key component of the trial design as it 
informs the calculation of the design effect, an inflation factor 
used to adjust standard sample size calculations. The sample 
size for a cluster randomized trial is commonly estimated 
by calculating the number of participants for an individual 
randomized trial with the same effect size, significance level, 
and power, and then multiplying the sample size by the design 
effect.28 Failure to incorporate the design effect into the 
sample size calculations results in a possible underestimation 
of the sample size necessary to detect the anticipated outcome 
difference between the intervention groups. Estimation of a 
design effect in the planning stages of a cluster randomized 
trial is challenging, particularly when preliminary data are 
not available to make reasonable assumptions.
Although accounting for correlations in sample size 
calculations and in the analyses approach is an important 
aspect in the design of cluster randomized trials, many cluster 
randomized trials still use inappropriate statistical methods 
or fail to report important methodological aspects. In a 
systematic review of 73 cluster randomized trials in residen-
tial facilities, only 27% reported accounting for clustering in 
sample size calculations and 74% in the analyses approach.29 
There is some evidence that the quality of reporting clus-
ter randomized trials has improved in a few aspects since 
the introduction of the extended Consolidated Standards 
of Reporting Trials (CONSORT) statement. However, no 
improvements were observed in reporting essential meth-
odological features.28,30 In a recently published systematic 
review, journal endorsement of the CONSORT statement 
was not associated with trial quality, but trials with support 
from statisticians and/or epidemiologists were more likely 
to account for clustering in sample size calculations and 
analyses.29
One unique challenge of cluster randomized trials is that 
successful randomization at the system level, resulting in 
balanced characteristics between clusters, does not guaran-
tee that characteristics are balanced at the individual level. 
Imbalance on the individual level is a threat to the internal 
validity of study results, and strategies to address possible 
imbalances should be considered at the design stage of the 
trial. Simple randomization techniques may pose a higher 
risk for covariate imbalance in cluster randomized trials, 
and more complex allocation techniques such as restricted 
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randomization including matching, stratification, and mini-
mization, as well as covariate-constrained randomization 
techniques, have been proposed to minimize the risk of 
imbalances.31
Outcome measures
Traditionally, primary and secondary endpoints in clinical 
trials have been chosen to be well defined clinically relevant 
outcome measures, such as mortality and disease-free sur-
vival, and measures indicating physiological and disease 
status changes. Although outcomes such as mortality and 
disease-free survival are certainly important to multiple 
stakeholders and should be part of the decision process, 
these endpoints do not reflect the patient’s experience and 
perspectives about the benefits and harms of an intervention. 
The value of incorporating patient-reported outcomes that 
allow conclusions about the effect of an intervention on 
patient’s symptoms, functional status, and quality of life has 
been extensively discussed and broadly accepted by the CER 
community as an important strategy to generate evidence 
that matters to patients and helps engage them in the clinical 
decision process.
Given the variety of instruments available to assess 
patient-reported outcomes, one of the challenges at the trial 
planning stage is to choose the appropriate outcome measure. 
A patient-reported outcome can be defined as a self-reported 
measure of patient health status, such as health-related qual-
ity of life, functional status, and patient satisfaction. Several 
patient-reported outcome measures including health-related 
quality of life have their roots in the social sciences using 
different conceptual frameworks as a basis for the instrument 
development.32 Instrument development is a complex process 
that involves patient input in qualitative assessments of the 
instrument, validation of the scoring system, and possibly 
different translations, and quantitative assessment of how to 
interpret score differences and establishment of meaningful 
thresholds.33,34 Clinical researchers may not yet be familiar 
with a meaningful interpretation of the mostly multidimen-
sional instruments, and it can be challenging to choose an 
instrument that best suits the specific objectives of the trial. 
Criteria to evaluate the appropriateness of an instrument 
include evidence for its reliability and validity in relation 
to the study population of the trial and its responsiveness to 
change.35 Patient-reported outcomes are often derived from 
multi-item instruments and summarized in scores, and may 
be less intuitive to interpret compared with outcomes such 
as mortality and disease-free survival. Some patient-reported 
outcome instruments allow derivation and definition of 
multiple endpoints (ie, overall score at the end of the study, 
mean change of score during follow-up, percent change of 
baseline score) and a careful decision about the endpoint 
definition and anticipated magnitude of the effect size should 
be taken at the designing stage to avoid  selective reporting 
of results and to assure appropriate power and sample size 
estimates.36–38
Several initiatives have been established to develop and 
standardize patient-reported outcome measures. The Patient 
Reported Outcomes Measurement Information System 
(PROMIS) is a US National Institutes of Health-funded 
network of outcomes researchers with the overarching goal 
of developing a framework for patient-reported outcomes.39 
Following the World Health Organization definition of 
health, PROMIS distinguishes between three areas of health 
(physical, mental, and social) and further defines subdomains, 
including physical function, fatigue, pain, emotional distress, 
social function, and global health. PROMIS measures were 
developed using data from general population samples 
across multiple chronic conditions. One advantage is that 
these universally relevant measures with a common metric 
can be compared across diseases and conditions. However, 
 universally relevant measures may not be as sensitive as 
disease-specific instruments to assess the health status and 
to detect changes over time in certain disease populations. 
 Controversy currently exists about the utilization of 
 universally relevant measures versus disease-specific mea-
sures, and future studies are warranted to better understand 
the relationship between these two types of measures and 
their application in different disease populations.40,41
Heterogeneity of outcomes measures makes it challenging 
to synthesize existing evidence through meta-analyses and 
systematic reviews. Achieving consensus about endpoints 
including patient-reported outcomes in clinical trials is 
crucial. Working groups worldwide have been launched to 
define and standardize disease-specific core outcome sets 
that are comparable across trials.42,43
Data collection and follow-up
Integration of electronic medical record information into 
clinical trials through automated processes is an emerging 
concept in the clinical trial enterprise.44,45 Effectiveness trials 
embedded in primary care and clinical settings can utilize 
patient data that have been routinely collected in clinical 
care through electronic medical records. This approach has 
advantages, as it allows collection of baseline and long-
term follow-up data for large and highly representable trial 
populations in a timely and cost-effective manner. Patients 





eligible for the trial can be identified automatically and 
 utilization of electronic record information allows com-
parisons of enrolled trial patients with those not enrolled 
to monitor the representativeness of the trial population. 
Linkages to other data sources, including national death 
registers, hospital records, and registries, allow capture of 
important outcome information and reduce the amount of 
loss to follow-up. Self-reported patient information collected 
through electronic devices can be linked to the trial database, 
enriching the trial data and allowing incorporation of patient-
reported outcomes.46
Data collection and patient follow-up through  utilization 
and linkage of electronic health records provides the 
CER enterprise with exciting opportunities. However, the 
 electronic health record has not been primarily designed 
for research purposes, which poses some major challenges. 
The data captured in an electronic health record may 
reflect the interactions of the patient with the health care 
system rather than a well defined disease status. Strategies 
to accurately “phenotype” patients according to the avail-
able electronic health record information have been devel-
oped, and efforts are underway to standardize and validate 
procedures across electronic medical record systems and 
institutions.47 Data quality is another issue that has been 
broadly discussed in the context of use of electronic medical 
records for research purposes, including data completeness 
and accuracy.  Missing data, erroneous data, inconsistencies 
among providers, across institutions, and over time, as well 
as data stored in noncoded text notes, are some of the data 
challenges identified.48
Complete, valid, and reliable baseline, follow-up, and 
endpoint data are crucial to assure high internal validity 
of trial results. A recently published study from Scotland 
compared cardiovascular endpoint detection through record 
linkage of death and hospitalization records with events that 
were reported through a standard clinical trial mechanism in 
the West of Scotland Coronary Prevention study.49 The study 
showed excellent matching between record linkage and end-
points assessed through standard trial mechanisms for unam-
biguous endpoints such as mortality, but complex diagnoses 
such as transient ischemic attack/stroke and identification of 
subsequent events was associated with imperfect matching 
of events. Important to note, the study was conducted in 
Scotland, a country with a unified health care system that 
facilitates patient follow-up. In a more scattered health care 
system with frequent insurance coverage transitions like the 
USA, patient follow-up through electronic health record link-
age may be limited and prone to missing information. Missing 
information can introduce bias and lead to false conclusions 
of intervention effectiveness. Although there are analytical 
strategies to handle missing information, the best approach 
is to prevent occurrence of missing information.50 Further 
studies will hopefully help to identify the best approach 
for electronic medical records’ utilization in clinical trials 
without compromising data quality and accuracy.
Conclusion
The evolving field of CER requires a shift in the traditional 
clinical trial paradigm and will continue to challenge and 
change the clinical trials’ landscape. Careful study design 
and consistent use of terminology and standards in report-
ing of trial results will facilitate meaningful interpretation 
and translation of findings. Incorporation of patient-reported 
outcomes into clinical trials will provide stakeholders 
with important information on patient’s experiences and 
perspectives. Identification of gaps in the field will foster 
development of novel methodological approaches. Key to 
a successful transition of the clinical research enterprise is 
investment in sustainable research infrastructures, further 
development and refinement of methodological approaches, 
and continuing training of the research community in relevant 
CER methods.
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